Bridgeworth LLC acquired a new position in shares of Eli Lilly And Co (NYSE:LLY) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 2,916 shares of the company’s stock, valued at approximately $224,000.
Several other institutional investors have also recently added to or reduced their stakes in the company. Avestar Capital LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth $100,000. Gradient Investments LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth $103,000. Front Row Advisors LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth $137,000. Silvant Capital Management LLC acquired a new stake in Eli Lilly And Co during the 1st quarter worth $150,000. Finally, Truewealth LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth $186,000. 76.10% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently commented on LLY. BMO Capital Markets reiterated a “sell” rating and set a $74.00 price target on shares of Eli Lilly And Co in a research note on Wednesday, April 4th. Credit Suisse Group restated a “hold” rating and issued a $80.00 price objective on shares of Eli Lilly And Co in a research note on Friday, February 2nd. TheStreet lowered shares of Eli Lilly And Co from a “b” rating to a “c” rating in a research note on Monday, March 5th. Barclays set a $98.00 price objective on shares of Eli Lilly And Co and gave the company a “buy” rating in a research note on Tuesday. Finally, Zacks Investment Research lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Monday, April 9th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $93.50.
In related news, SVP Susan Mahony sold 22,544 shares of the business’s stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $80.09, for a total transaction of $1,805,548.96. Following the sale, the senior vice president now owns 45,652 shares of the company’s stock, valued at $3,656,268.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Donald A. Zakrowski sold 860 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 360,596 shares of company stock worth $29,260,282. Company insiders own 0.11% of the company’s stock.
Shares of Eli Lilly And Co stock opened at $82.77 on Friday. Eli Lilly And Co has a 52-week low of $73.69 and a 52-week high of $89.09. The company has a current ratio of 1.41, a quick ratio of 1.01 and a debt-to-equity ratio of 0.64. The stock has a market cap of $89.74 billion, a PE ratio of 19.34, a PEG ratio of 1.46 and a beta of 0.26.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.21. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. The business had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.51 billion. During the same period in the previous year, the business posted $0.98 earnings per share. The business’s revenue was up 9.0% compared to the same quarter last year. equities analysts anticipate that Eli Lilly And Co will post 5.16 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be paid a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.72%. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.